ARD-2051 is a highly effective orally bioavailable degrader designed to target the androgen receptor (AR) for proteolysis. This compound demonstrates significant potency in degrading AR protein in prostate cancer cell lines such as LNCaP and VCaP, making it valuable for research into AR-related pathways.
Usually ships within 24 hours.